Andrew Corbett

Andrew Corbett is currently the Medical Lead for Friedreich Ataxia at the Biogen Rare Disease International Center of Excellence (ICOE) in Switzerland and serves as the Global Co-Chair of the organization’s LGBTQ+ Employee Resource Network. Corbett has over five years of experience in launching products in rare diseases across multiple indications and countries, with these launches recognized as the most successful of their years by the global operating company. Previously, Corbett held various roles at Eli Lilly and Company, Janssen, and Biogen, focusing on oncology and rare disease therapeutic areas. With a Bachelor of Nursing from Griffith University and a Master's in Clinical Research Management from the University of Sydney, Corbett emphasizes team success and the importance of compassionate access to life-saving treatments.